JP2018506983A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506983A5 JP2018506983A5 JP2017545941A JP2017545941A JP2018506983A5 JP 2018506983 A5 JP2018506983 A5 JP 2018506983A5 JP 2017545941 A JP2017545941 A JP 2017545941A JP 2017545941 A JP2017545941 A JP 2017545941A JP 2018506983 A5 JP2018506983 A5 JP 2018506983A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- retroviral
- vector
- mitogenic
- lentiviral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims description 50
- 210000004027 cell Anatomy 0.000 claims description 45
- 230000001177 retroviral effect Effects 0.000 claims description 37
- 108091005703 transmembrane proteins Proteins 0.000 claims description 34
- 102000035160 transmembrane proteins Human genes 0.000 claims description 34
- 230000002297 mitogenic effect Effects 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 24
- 239000013603 viral vector Substances 0.000 claims description 22
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 20
- 230000006044 T cell activation Effects 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 102000004127 Cytokines Human genes 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 238000004806 packaging method and process Methods 0.000 claims description 11
- 229960002685 biotin Drugs 0.000 claims description 10
- 235000020958 biotin Nutrition 0.000 claims description 10
- 239000011616 biotin Substances 0.000 claims description 10
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 9
- 108010090804 Streptavidin Proteins 0.000 claims description 8
- 108700004030 rev Genes Proteins 0.000 claims description 6
- 241001430294 unidentified retrovirus Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 101150098213 rev gene Proteins 0.000 claims description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 4
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100021696 Syncytin-1 Human genes 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 210000004779 membrane envelope Anatomy 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 241001504519 Papio ursinus Species 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108700004026 gag Genes Proteins 0.000 claims 1
- 108700004029 pol Genes Proteins 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201503500A GB201503500D0 (en) | 2015-03-02 | 2015-03-02 | Cell |
| GB1503500.9 | 2015-03-02 | ||
| PCT/GB2016/050537 WO2016139463A1 (en) | 2015-03-02 | 2016-03-01 | Retroviral and lentiviral vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020050861A Division JP2020092722A (ja) | 2015-03-02 | 2020-03-23 | レトロウイルスおよびレンチウイルスベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506983A JP2018506983A (ja) | 2018-03-15 |
| JP2018506983A5 true JP2018506983A5 (https=) | 2019-01-24 |
| JP6695347B2 JP6695347B2 (ja) | 2020-05-20 |
Family
ID=52876362
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545941A Active JP6695347B2 (ja) | 2015-03-02 | 2016-03-01 | レトロウイルスおよびレンチウイルスベクター |
| JP2020050861A Withdrawn JP2020092722A (ja) | 2015-03-02 | 2020-03-23 | レトロウイルスおよびレンチウイルスベクター |
| JP2023029559A Withdrawn JP2023060000A (ja) | 2015-03-02 | 2023-02-28 | レトロウイルスおよびレンチウイルスベクター |
| JP2025227149A Pending JP2026026312A (ja) | 2015-03-02 | 2025-12-03 | レトロウイルスおよびレンチウイルスベクター |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020050861A Withdrawn JP2020092722A (ja) | 2015-03-02 | 2020-03-23 | レトロウイルスおよびレンチウイルスベクター |
| JP2023029559A Withdrawn JP2023060000A (ja) | 2015-03-02 | 2023-02-28 | レトロウイルスおよびレンチウイルスベクター |
| JP2025227149A Pending JP2026026312A (ja) | 2015-03-02 | 2025-12-03 | レトロウイルスおよびレンチウイルスベクター |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10954530B2 (https=) |
| EP (2) | EP3265570B2 (https=) |
| JP (4) | JP6695347B2 (https=) |
| KR (1) | KR20180002602A (https=) |
| CN (1) | CN107406860A (https=) |
| AU (1) | AU2016227474A1 (https=) |
| BR (1) | BR112017018251A2 (https=) |
| CA (1) | CA2977472A1 (https=) |
| CL (1) | CL2017002199A1 (https=) |
| ES (1) | ES2877398T5 (https=) |
| GB (1) | GB201503500D0 (https=) |
| IL (1) | IL253820B (https=) |
| MX (1) | MX2017010553A (https=) |
| RU (1) | RU2017133854A (https=) |
| SG (1) | SG11201706721PA (https=) |
| WO (1) | WO2016139463A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014338864C1 (en) | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
| GB201415344D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Protein |
| KR101697473B1 (ko) | 2014-11-26 | 2017-01-18 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
| PE20180241A1 (es) | 2015-04-30 | 2018-01-31 | Psioxus Therapeutics Ltd | Adenovirus oncolitico que codifica una proteina b7 |
| US10046317B2 (en) * | 2015-08-11 | 2018-08-14 | Chevron U.S.A. Inc. | Middle distillate hydrocracking catalyst containing zeolite beta with low OD acidity and large domain size |
| US11248238B2 (en) | 2015-10-22 | 2022-02-15 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
| EA201891022A1 (ru) * | 2015-12-17 | 2019-01-31 | Псайоксус Терапьютикс Лимитед | Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| IL261713B2 (en) * | 2016-03-19 | 2023-09-01 | F1 Oncology Inc | Methods and preparations for the transfer of lymphocytes and their regulated expansion |
| GB201614093D0 (en) * | 2016-08-17 | 2016-09-28 | Autolus Ltd | Vector |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CN119614520A (zh) | 2016-08-29 | 2025-03-14 | 阿卡米斯生物公司 | 携带双特异性t细胞衔接器的腺病毒 |
| AU2017370644A1 (en) * | 2016-12-05 | 2019-06-13 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
| WO2018120843A1 (zh) * | 2016-12-30 | 2018-07-05 | 上海近岸生物科技有限公司 | 一种三功能分子及其应用 |
| EP3575319A4 (en) * | 2016-12-30 | 2021-03-10 | Shanghai Sinobio Biotech Co., Ltd. | BIFUNCTIONAL MOLECULE AND USE OF IT |
| AU2018226884B2 (en) * | 2017-03-03 | 2024-11-07 | Exuma Biotech, Corp. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| EP3633029A4 (en) * | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| CN111479921B (zh) * | 2017-09-18 | 2024-08-02 | 埃克苏马生物技术公司 | 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物 |
| US11957715B2 (en) * | 2017-12-20 | 2024-04-16 | Miltenyi Biotec B.V. & Co. KG | Method for NK cell transduction |
| CN112262214A (zh) * | 2018-04-12 | 2021-01-22 | 优莫佳生物制药股份有限公司 | 病毒载体及包装细胞系 |
| PT3835415T (pt) * | 2018-08-10 | 2024-12-18 | Univ Kyoto | Método para produção de células positivas para cd3 |
| AU2019333324B2 (en) * | 2018-09-02 | 2025-08-28 | Exuma Biotech, Corp | Methods and compositions for genetically modifying lymphocytes in blood or in enriched PBMCs |
| MY199770A (en) | 2018-11-14 | 2023-11-22 | Green Cross Lab Cell Corp | Method for culturing cord blood-derived natural killer cells using transformed t cells |
| WO2020106992A1 (en) | 2018-11-21 | 2020-05-28 | Umoja Biopharma, Inc. | Multicistronic vector for surface engineering lentiviral particles |
| CN109722420A (zh) * | 2019-03-15 | 2019-05-07 | 江苏艾洛特医药研究院有限公司 | 一种改良嵌合抗原受体t细胞的制备及其应用 |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| US20240122978A1 (en) * | 2019-10-16 | 2024-04-18 | Umoja Biopharma, Inc. | Retroviral vector for univeral receptor therapy |
| US20230348624A1 (en) | 2020-01-30 | 2023-11-02 | Umoja Biopharma, Inc. | Bispecific transduction enhancer |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| CA3199588A1 (en) | 2020-11-20 | 2022-05-27 | Andrew Scharenberg | Vector system for delivery of multiple polynucleotides and uses thereof |
| MX2023008831A (es) | 2021-01-27 | 2023-10-19 | Umoja Biopharma Inc | Lentivirus para generar células que expresan receptores de antígeno quimérico anti-cd19. |
| CN112941039A (zh) * | 2021-02-01 | 2021-06-11 | 南京大学 | 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用 |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023143209A1 (zh) * | 2022-01-25 | 2023-08-03 | 广东东阳光药业股份有限公司 | 病毒载体及其应用 |
| WO2023198828A1 (en) | 2022-04-13 | 2023-10-19 | Universitat Autònoma De Barcelona | Treatment of neuromuscular diseases via gene therapy that expresses klotho protein |
| US20250382586A1 (en) | 2022-05-17 | 2025-12-18 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
| JP2026500897A (ja) | 2022-11-04 | 2026-01-09 | ウモジャ バイオファーマ インコーポレイテッド | 融合分子を呈示するレンチウイルス粒子およびその使用 |
| TW202434621A (zh) | 2022-11-04 | 2024-09-01 | 美商優莫佳生物製藥有限公司 | 多核苷酸構築體及相關病毒載體及方法 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| CN120769904A (zh) * | 2023-02-27 | 2025-10-10 | 上海君赛生物科技有限公司 | 表达膜结合细胞因子的肿瘤浸润淋巴细胞 |
| KR20260005358A (ko) * | 2023-04-27 | 2026-01-09 | 밀테니 비오텍 비.브이. & 씨오. 케이지 | 항-cd3 디스플레이를 갖는 슈도타이핑된 레트로바이러스 벡터 입자 |
| WO2024238153A1 (en) | 2023-05-15 | 2024-11-21 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd20 chimeric antigen receptors |
| CN116496417B (zh) * | 2023-06-27 | 2023-10-10 | 北京市肿瘤防治研究所 | 含有膜型il7的融合蛋白及t细胞 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025072257A1 (en) * | 2023-09-25 | 2025-04-03 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| AU2024353718A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| AU2024353243A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| WO2025090978A1 (en) | 2023-10-26 | 2025-05-01 | Cargo Therapeutics, Inc. | Modified immune effector cells |
| WO2025149068A1 (zh) * | 2024-01-10 | 2025-07-17 | 深圳市济因生物科技有限公司 | 一种病毒颗粒及其制备方法与应用 |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2025235604A1 (en) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Fusion protein for use as immune cell engager |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
| WO2026052028A1 (zh) * | 2024-09-05 | 2026-03-12 | 深圳市济因生物科技有限公司 | 一种制备表达car的t细胞的方法及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7097494A (en) * | 1993-06-01 | 1994-12-20 | Targeted Genetics Corporation | Envelope fusion vectors for use in gene delivery |
| JPH11510050A (ja) * | 1995-07-25 | 1999-09-07 | イントロヘーネ ベスローテン フェンノートシャップ | 標的遺伝子送達のための方法および手段 |
| CA2518383A1 (en) | 2003-03-07 | 2004-09-23 | University Of Utah Research Foundation | Il-2 transmembrane constructs |
| EP1769078A1 (en) * | 2004-07-01 | 2007-04-04 | VIRxSYS Corporation | Vector packaging cell line |
| MX2007006832A (es) * | 2004-12-13 | 2007-08-07 | Cytos Biotechnology Ag | Arreglos de antigeno interleucina 15 y usos de los mismos. |
| WO2007095201A2 (en) * | 2006-02-15 | 2007-08-23 | The Regents Of The University Of California | Pseudotyped retroviral vectors and methods of use thereof |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| GB0920775D0 (en) | 2009-11-26 | 2010-01-13 | King S College | Cells |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| GB201415344D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Protein |
| GB201614093D0 (en) | 2016-08-17 | 2016-09-28 | Autolus Ltd | Vector |
| GB201910651D0 (en) | 2019-07-25 | 2019-09-11 | Autolus Ltd | Virus-like particle |
-
2015
- 2015-03-02 GB GB201503500A patent/GB201503500D0/en not_active Ceased
-
2016
- 2016-03-01 BR BR112017018251-3A patent/BR112017018251A2/pt not_active Application Discontinuation
- 2016-03-01 CA CA2977472A patent/CA2977472A1/en not_active Abandoned
- 2016-03-01 EP EP16709502.5A patent/EP3265570B2/en active Active
- 2016-03-01 CN CN201680013282.6A patent/CN107406860A/zh active Pending
- 2016-03-01 EP EP21171660.0A patent/EP3904523A1/en active Pending
- 2016-03-01 US US15/554,499 patent/US10954530B2/en active Active
- 2016-03-01 AU AU2016227474A patent/AU2016227474A1/en not_active Abandoned
- 2016-03-01 KR KR1020177027017A patent/KR20180002602A/ko not_active Abandoned
- 2016-03-01 SG SG11201706721PA patent/SG11201706721PA/en unknown
- 2016-03-01 RU RU2017133854A patent/RU2017133854A/ru not_active Application Discontinuation
- 2016-03-01 ES ES16709502T patent/ES2877398T5/es active Active
- 2016-03-01 MX MX2017010553A patent/MX2017010553A/es unknown
- 2016-03-01 WO PCT/GB2016/050537 patent/WO2016139463A1/en not_active Ceased
- 2016-03-01 JP JP2017545941A patent/JP6695347B2/ja active Active
-
2017
- 2017-08-03 IL IL253820A patent/IL253820B/en active IP Right Grant
- 2017-08-30 CL CL2017002199A patent/CL2017002199A1/es unknown
-
2020
- 2020-03-23 JP JP2020050861A patent/JP2020092722A/ja not_active Withdrawn
-
2021
- 2021-03-04 US US17/192,561 patent/US11814641B2/en active Active
-
2023
- 2023-02-28 JP JP2023029559A patent/JP2023060000A/ja not_active Withdrawn
-
2024
- 2024-12-19 US US18/987,004 patent/US20250388929A1/en active Pending
-
2025
- 2025-12-03 JP JP2025227149A patent/JP2026026312A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506983A5 (https=) | ||
| RU2017133854A (ru) | Вектор | |
| Kolchinsky et al. | Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops | |
| Yang et al. | Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers | |
| Mebatsion et al. | A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells | |
| Egelhofer et al. | Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides | |
| Yang et al. | Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins | |
| Sullivan et al. | Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies | |
| JP2019509063A5 (https=) | ||
| EP2583974A1 (en) | Pseudotyping of foamy viruses | |
| JP2021502799A (ja) | レトロウイルスベクター | |
| Kayman et al. | The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system | |
| US20240124848A1 (en) | Stable lentivirus packaging cell line and preparation method therefor | |
| Swanstrom et al. | Sequencing the biology of entry: the retroviral env gene | |
| US20240401077A1 (en) | Koala retrovirus envelope gylcoproteins and uses thereof | |
| US20240190988A1 (en) | Novel chimeric antigen receptors and libraries | |
| Vahlenkamp et al. | A single amino acid substitution in the transmembrane envelope glycoprotein of feline immunodeficiency virus alters cellular tropism | |
| Muratori et al. | Lentivirus-based virus-like particles as a new protein delivery tool | |
| Buffa et al. | A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1) HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice | |
| CN106755109A (zh) | 一种表达人cd19和cd20嵌合抗原受体基因的慢病毒载体 | |
| Steidl et al. | Coreceptor Switch of [MLV (SIVagm)] pseudotype vectors by V3-loop exchange | |
| JP2014528729A (ja) | ウイルスベクター精製システム | |
| Tsukahara et al. | Characterization of envelope glycoprotein mutants for human T-cell leukemia virus type 1 infectivity and immortalization | |
| WO2024220597A2 (en) | Digital droplet based assay for detecting replication competent lentiviral vector | |
| EP1739180A1 (en) | T cell line-based packaging cell line for the production of retroviruses by enriching of CD3 expressing cells |